Carcinoma of the prostate. Hormonal therapy
Authors:
- John T. GrayhackJGJohn T. Grayhack
- Thomas C. KeelerTKThomas C. Keeler
- James M. KozlowskiJKJames M. Kozlowski
Abstract
A selective review of the literature regarding hormonal therapy for patients with carcinoma of the prostate is presented to assess the current status of the following: therapeutic advantages, disadvantages and risks of alternate approaches to hormonal therapy; observations to predict the magnitude and duration of response to therapy; indications for initiating hormone therapy; the short-term and long-term effects of therapy; and role of hormone therapy in patients with recurrent tumor activity after initial hormonal measures.Keywords
This publication has 121 references indexed in Scilit:
- Expression ofrasOncogene p21 in Prostate CancerNew England Journal of Medicine, 1986
- Treatment of advanced prostatic cancer, resistant to conventional therapy with aminoglutethimideEuropean Journal of Cancer and Clinical Oncology, 1985
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Carcinoma of the prostate: Relationship of pretreatment hormone levels to survivalEuropean Journal of Cancer and Clinical Oncology, 1984
- Clinical applications and value of receptor levels in treatment of prostate cancerThe Prostate, 1984
- The use of multiparameter flow cytometry to assess tumor cell heterogeneity and grade prostate cancerThe Prostate, 1984
- Nuclear androgen receptor assay in biopsy‐size specimens of human prostatic tissueThe Prostate, 1982
- Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancerThe Prostate, 1981
- Treatment of Advanced Prostatic Cancer with Parenteral Cyproterone Acetate: A Phase III Randomised Trial*British Journal of Urology, 1980
- Serial Bone Scanning: The Assessment of Treatment Response in Carcinoma of the ProstateBritish Journal of Urology, 1978